middle.news
How Nexsen’s FDA Pre-Submission Could Transform Rapid Maternal Diagnostics
10:22pm on Thursday 29th of January, 2026 AEDT
•
Healthcare
Read Story
How Nexsen’s FDA Pre-Submission Could Transform Rapid Maternal Diagnostics
10:22pm on Thursday 29th of January, 2026 AEDT
Key Points
FDA 510(k) pre-submission lodged for GBS rapid sensor
Cash reserves of $6.88 million post-IPO costs
Clinical validation underway at Northern Health
Appointment of Professor Shekhar Kumta to Board
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NXN
OPEN ARTICLE